Biotech Firm Sarepta Surges 40% on Positive Test Results

Sarepta Therapeutics Inc. (SRPT) soared nearly 40% in Tuesday trading after publishing impressive results for a new gene therapy designed to treat a rare form of muscular dystrophy. However, the news pushed shares of rival drugmaker PTC Therapeutics Inc. (PTCT)  down by almost the same percentage,

Sarepta rose $38.69 -- or 36.8% -- to $143.93 after results for its drug to treat Duchenne muscular dystrophy outperformed Wall Street's expectations. But PTC Therapeutics Inc. (PTCT)  , which makes a drug designed to treat the same disease, tumbled $14.64 -- 30.6% -- to $33.24 on the news.

PTC Therapeutics' fall came just one day after its stock rose 28% after it published positive results for a new spinal muscular atrophy treatment.

More from Stocks

FedEx Tanks After It Fails to Deliver on Earnings

FedEx Tanks After It Fails to Deliver on Earnings

FedEx's Free Cash Flow Offers a Positive Signal for a Sagging Stock

FedEx's Free Cash Flow Offers a Positive Signal for a Sagging Stock

Dow, Stocks Shrug Off Trade War Escalation, End Higher

Dow, Stocks Shrug Off Trade War Escalation, End Higher

Chart of the Day: How Tariff Talk Hurts FedEx Stock

Chart of the Day: How Tariff Talk Hurts FedEx Stock

Experts Are High on Cannabis Stocks' 2019 Prospects

Experts Are High on Cannabis Stocks' 2019 Prospects